10/588555 IAP11 Rec'd PCT/PTO 04 AUG 2006

Attorney Docket No.: 10517.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al

Confirmation No: TBA

Serial No.: To be assigned

Group Art Unit: TBA

Filed: August 4, 2006

Examiner: TBA

For: Protease Variants

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: August 4, 2006

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600

New York, NY 10110

(212) 840-0097

10/588555 IAP11 Rec d PCT/PTO 04 AUG 2006 PTO/SB/0BA (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Par	perwork Reduction	Act of 1995, no pers	ons are required to r	respond to a collection of information unles	s it contains a valid Olvib control number.		
Substitute fo	or form 1449A/PTO			Compl	Complete if Known		
				Application Number	To be assigned		
	INFORMAT	ION DISCLOS	URE	Filing Date	August 4, 2006		
	STATEMEN	IT BY APPLIC	ANT	First Named Inventor	Svendsen et al		
	(use as many sheets as necessary)			Art Unit	TBA		
`		Examiner Name	TBA				
Sheet	1	of	2	Attorney Docket Number	10517.204-US		

U.S PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<u> </u>					
			<u> </u>			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т 6		
		WO 01/16285	03/08/2001	Novozymes A/S				
	ļ							
<u> </u>	- 		·			<u> </u>		
	<u> </u>					-		
	 							
	 							
								
· · · · · · · · · · · · · · · · · · ·	†							
	1							
	ļ							
	 		ļ					
	+							
	 		· · · · · · · · · · · · · · · · · · ·					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

10/588555 IAPTI Rec'd PCT/PTO U4 AUG 2006 PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reduction F	ACLOI 1995, NO PEIS	sons are required to i	espond to a collection of information unles	S IL CONTAINS A VAIID COND CONTO HUMBER.		
Substitute fo	r form 1449A/PTO			Compl	Complete if Known		
				Application Number	To be assigned		
1	INFORMATI	ON DISCLOS	SURE	Filing Date	August 4, 2006		
]	STATEMEN	T BY APPLIC	ANT	First Named Inventor	Svendsen et al		
	(use as many	sheets as necessa	ary)	Art Unit	TBA		
			•	Examiner Name	TBA		
Sheet	2	of	2	Attorney Docket Number	10517.204-US		

Examiner's	Cite	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
nitials	No. 1	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T²
		KAKUDO et al., The Journal of Biological Chemistry, Vol. 267, No. 33, pp. 23782-23788 (November 25, 1992)	
		MEIJERS et al., Biochemistry, Vol. 43, pp. 2784-2791 (2004)	
		PRASAD et al., Acta Crystallographica D60, pp. 256-259 (2004)	
		CAVARELLI et al., Structure, Vol. 5, No. 6, pp. 813-824 (1997)	
		RAO et al., Microbiology and Molecular Biology Reviews, Vol. 62, No. 3, pp. 597-635 (Sept. 1998)	
		OKAMOTO et al., Appl. Microbiol. Biotechnol., Vol. 48, pp. 27-33 (1997)	
			_

Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.